Generated by AI
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative immuno-oncology therapies for cancer. The company’s current portfolio centers on LOQTORZI, an approved PD-1 inhibitor used in oncology treatment, alongside additional clinical-stage candidates designed to address several solid tumors and tumor types. Coherus Oncology works across research, regulatory development, manufacturing, and commercialization, with an emphasis on combination therapies that may expand the use of its cancer medicines. Its business is concentrated on oncology therapeutics, reflecting a focused role in the cancer drug market and a strategy built around antibody-based and immune-based treatments. Based in Redwood City, California, Coherus Oncology serves as a specialized player in the U.S. biopharmaceutical sector, with its commercial activities and pipeline development aimed at improving treatment options in modern oncology.
Website333 Twin Dolphin Drive
Redwood City, CA, 94065
United States
The latest articles about CHRS.
Coherus Oncology Inc (CHRS) trimmed headcount by 30% and lowered its breakeven threshold while revising 2026 Loqtorzi guidance to $54-$57 million amid a sub-12-month cash runway.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 16's posts. Generated by AI.
Summary of Dec 5's posts. Generated by AI.
Summary of Oct 29's posts. Generated by AI.
Investors talking about CHRS also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.